Clinical trial
The Role of Bacteria and Genetic Variations in Cystic Fibrosis
NCT00043225 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00043225 |
|---|---|
| Title | The Role of Bacteria and Genetic Variations in Cystic Fibrosis |
| Official title | Clinical Course in Cystic Fibrosis: The Effects of Pseudomonas Aeruginosa and Potential Modifier Genes |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Study type | Observational |
| Conditions | Psuedomas Infection, Cystic Fibrosis |
| Enrollment | 76 |
| Start date | Jun 20, 2001 |
| Primary completion | Jul 10, 2018 |
| Completion | Jul 10, 2018 |
| First posted | Aug 7, 2002 |
| Last update posted | Jun 29, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: